Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
EPPIK (IgAN, IgAV, Alport Syndrome)
The EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome
Brief Description
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with:
• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)
See also the EPPIK Clinical Study for Children with FSGS and MCD.
Trial Physician / Study Coordinator
Belle Pace
Email PhoneSite Name
Fink Children's Ambulatory Care
150 East 32nd Street, NY, NY 10016
Estimated enrollment
The entire EPPIK study (including FSGS, MCD, IgAN, IgAV and Alport Syndrome) will enroll approximately 57 children.
Estimated end date
To be determined
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
EPPIK (IgAN, IgAV, Alport Syndrome)
The EPPIK Clinical Study for Children with IgAN, IgAV, and Alport Syndrome
Brief Description
The EPPIK study will evaluate the investigational drug, sparsentan, for the treatment of selected rare kidney diseases. The investigational approach is to lower proteinuria levels with sparsentan and slow the loss of kidney function in children ages 2-17 with:
• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)
See also the EPPIK Clinical Study for Children with FSGS and MCD.
Trial is for people with
For children ages 2-17 with:
• IgA nephropathy (IgAN), also known as Berger’s disease
• IgA vasculitis (IgAV), also known as Henoch-Schönlein purpura
• Alport syndrome (AS)
Study Goal
The goals of the study are to evaluate the safety and effectiveness of sparsentan on children with FSGS, MCD, IgAN, IgAV and Alport syndrome.
What is involved for the Patient?
Patients will participate for about 2 years and 3 months and will receive sparsentan.
About the drug or intervention
Participants receive sparsentan, the investigational drug, taken as a liquid by mouth.